Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selicrelumab + Atezolizumab in R/R B-Cell Lymphoma
NCT03892525Phase 1Terminated
- Sponsor
- LYSARC
- Start
- Jul 2019
- Primary completion
- Apr 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of selicrelumab in B-cell non-Hodgkin lymphoma, sponsored by LYSARC. Primary endpoint: Optimal dose of intratumoral Selicrelumab in combination with flat doses of Atezolizumab IV at 21 days. Started Jul 2019; status: terminated.
02
Drugs
selicrelumab
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT03892525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03892525.